Neurotech International Ltd News

Neurotech International Ltd: Positive Genomic Effects of NTI164 in PANDAS/PANS Patients

Nov 15 05:20

Neurotech International Ltd: New Scientific Publication Highlights Benefits of NTI164

Nov 12 09:19

Neurotech International Ltd: Neurotech Appoints Dr Anthony Filippis as MD/CEO

Nov 11 05:27

Neurotech International Ltd: US FDA Response to Orphan Drug Request in PANDAS/PANS

Oct 4 06:52

Neurotech International Ltd: Change of Director's Interest Notice

Sep 20 16:25

Neurotech International Ltd: NTI164 Reverses Immune Dysregulation in PANDAS/PANS Children

Sep 9 07:00

Neurotech International Ltd: Neurotech ESG Report

Aug 30 14:45

Neurotech International Ltd: US FDA orphan drug designation requested for Rett Syndrome

Aug 30 06:49

Neurotech International Ltd: Appendix 4G and Corporate Governance Statement

Aug 26 17:05

Neurotech International Ltd: Neurotech Global Partnering and Registration Strategy

Aug 12 06:15

Neurotech International Ltd: Further Significant Improvement in Rett Syndrome Patients

Jul 31 07:02

Neurotech International Ltd: Quarterly Activities/Appendix 4C Cash Flow Report

Jul 25 07:07

Neurotech International Ltd: Phase II/III autism trial shows further benefits

Jul 18 06:25

Neurotech International Ltd: Significant improvement in Autism patients at 12 weeks

Jul 10 06:35

Neurotech International Ltd: US FDA orphan drug designation requested for PANDAS/PANS

Jul 9 06:37

Neurotech International Ltd: Appointment of Chief Medical Officer

Jul 5 06:44

Neurotech International Ltd: Release of Shares from Voluntary Escrow

Jul 1 14:47

Neurotech International Ltd: Expert PANDAS/PANS panel established post TGA meeting

Jun 28 07:16

Neurotech International Ltd: Phase I/II Autism Patients Meet 2 Years of NTI164 Treatment

Jun 17 07:04

Neurotech International Ltd: Further clinical benefit at 52 weeks in PANDAS/PANS patients

Jun 6 06:43